A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2003.11.196 ◽

2004 ◽

Vol 23 (2) ◽

pp. S107 ◽

Cited By ~ 1

Author(s):

M Cantarovich ◽

H Ross ◽

J Arizon ◽

J Orus ◽

L Straatman ◽

...

Keyword(s):

Adaptive Design ◽

De Novo ◽

Cardiac Transplant ◽

Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A 12-MONTH, MULTICENTER, RANDOMIZED, ADAPTIVE DESIGN, OPEN-LABEL STUDY TO EVALUATE THE BENEFIT OF C2 HOUR MONITORING OF NEORAL ON SAFETY AND EFFICACY OUTCOMES IN DE NOVO CARDIAC TRANSPLANT RECIPIENTS RECEIVING BASILIXIMAB INDUCTION

10.1097/00007890-200407271-01123 ◽

2004 ◽

Vol 78 ◽

pp. 420

Author(s):

M Cantarovich ◽

H Ross ◽

J Arizon ◽

M A. Gomez ◽

L Straatman ◽

...

Keyword(s):

Adaptive Design ◽

De Novo ◽

Cardiac Transplant ◽

Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

249: A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2009.11.260 ◽

2010 ◽

Vol 29 (2) ◽

pp. S85-S85

Author(s):

A. Zuckermann ◽

A. Keogh ◽

M.G. Crespo-Leiro ◽

D. Mancini ◽

F. Gonzalez-Vilchez ◽

...

Keyword(s):

Renal Insufficiency ◽

Calcineurin Inhibitor ◽

Cardiac Transplant ◽

Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Continued Use ◽

Moderate Renal Insufficiency

A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DIFFERENT SIROLIMUS (SRL) REGIMENS WITH TACROLIMUS (TAC) + MYCOPHENOLATE MOFETIL (MMF) IN DE NOVO RENAL ALLOGRAFT RECIPIENTS: PRELIMINARY 2-YEAR SAFETY RESULTS FROM THE ORION TRIAL

10.1097/01.tp.0000332240.81508.2b ◽

2008 ◽

Vol 86 (Supplement) ◽

pp. 156 ◽

Cited By ~ 7

Author(s):

S Flechner ◽

S Cockfield ◽

J Grinyo ◽

G Russ ◽

K M. Wissing ◽

...

Keyword(s):

Mycophenolate Mofetil ◽

Renal Allograft ◽

De Novo ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study)

10.1097/tp.0000000000002851 ◽

2020 ◽

Vol 104 (2) ◽

pp. 374-386 ◽

Cited By ~ 1

Author(s):

Tommaso Maria Manzia ◽

Mario Carmellini ◽

Paola Todeschini ◽

Antonio Secchi ◽

Silvio Sandrini ◽

...

Keyword(s):

Wound Healing ◽

Kidney Transplant ◽

De Novo ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

The Impact

A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE SAFETY AND EFFICACY OF CYCLOSPORINE (CSA) DOSE REDUCTION WITH CSA ELIMINATION IN DE NOVO RENAL ALLOGRAFT PATIENTS RECEIVING SIROLIMUS

10.1097/01.tp.0000332260.21413.c3 ◽

2008 ◽

Vol 86 (Supplement) ◽

pp. 157

Author(s):

H Tedesco-Silva ◽

J M. Pestana ◽

F Alfieri ◽

S See-Tai

Keyword(s):

Dose Reduction ◽

Renal Allograft ◽

De Novo ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study

10.1097/01.tp.0000140486.97461.49 ◽

2004 ◽

Vol 78 (9) ◽

pp. 1332-1340 ◽

Cited By ~ 147

Author(s):

Bj??rn Nashan ◽

John Curtis ◽

Claudio Ponticelli ◽

Georges Mourad ◽

Jonathan Jaffe ◽

...

Keyword(s):

Renal Transplant ◽

Phase Ii ◽

De Novo ◽

Renal Transplant Recipients ◽

Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study

INTENSIFIED DOSE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) FOR 6 WEEKS, IN COMBINATION WITH ANTI-IL2R INDUCTION, CYCLOSPORINE MICRO-EMULSION (CSA-ME) WITH OR WITHOUT STEROIDS, IN ADULT DE NOVO LOW IMMUNOLOGICAL RISK KIDNEY TRANSPLANT RECIPIENTS: FINAL EFFICACY AND SAFETY RESULTS OF A PROSPECTIVE MULTICENTER RANDOMIZED OPEN-LABEL STUDY: DOMINOS STUDY.

10.1097/00007890-201007272-00215 ◽

2010 ◽

Vol 90 ◽

pp. 111

Author(s):

G. Touchard ◽

Y. Lebranchu ◽

G. Mourad ◽

L. Rostaing ◽

S. Quere ◽

...

Keyword(s):

Kidney Transplant ◽

De Novo ◽

Efficacy And Safety ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Micro Emulsion ◽

Enteric Coated

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Case Medical Research ◽

10.31525/ct1-nct03977792 ◽

2019 ◽

Author(s):

Keyword(s):

Herpes Labialis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Recurrent Herpes ◽

Cold Sores

An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

Case Medical Research ◽

10.31525/ct1-nct04180774 ◽

2019 ◽

Author(s):

Keyword(s):

Malignant Melanoma ◽

Tumor Cell ◽

Renal Cell ◽

Cell Cancer ◽

Locally Advanced ◽

Metastatic Malignant Melanoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽